Watch the Latest Episode
Frankly with Dean LaFerla
Episode 17 –
Professor Joshua Grill
Dean Frank LaFerla is joined by Professor Joshua Grill, director of the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), who talks about the promising new Alzheimer’s disease drug, lecanemab, and what it means for Alzheimer’s patients and the research community.
Watch Now
Catch up on all the episodes.
Frankly with Dean LaFerla Ep7 – Dean LaFerla welcomes Molecular Biology and Biochemistry Chair and Professor Chris Hughes, who introduces the audience to his bioengineered micro-organ system, complete with blood vessels. Professor Hughes explains how his “organ-on-a-chip” technology can model human organ systems and what that means for future drug development.
Frankly with Dean LaFerla Ep9 – In this episode, Developmental and Cell Biology Professor Peter Donovan turns the tables on Dean Frank LaFerla and interviews him for Alzheimer’s Awareness Month. The two discuss important facts about Alzheimer’s and Dean LaFerla’s contributions to Alzheimer’s research.
Frankly with Dean LaFerla Ep10 – Dean LaFerla welcomes Joshua Grill, associate professor of neurobiology and behavior and director of The UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), for Alzheimer’s Awareness Month. Professor Grill reviews his latest research on clinical trials in Alzheimer’s disease therapeutic research.
Frankly with Dean LaFerla Ep11 – In this episode, Dean LaFerla is joined by Molecular Biology and Biochemistry Associate Professor Katrine Whiteson. Professor Whiteson is also the co-director of the UC Irvine Microbiome Initiative. She and Dean LaFerla discuss her new project to monitor the COVID-19 virus in Southern California sewage.
Frankly with Dean LaFerla Ep17 – Dean Frank LaFerla is joined by Professor Joshua Grill, director of the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), who talks about the promising new Alzheimer’s disease drug, lecanemab, and what it means for Alzheimer’s patients and the research community.